Essex Investment Management Co. LLC cut its position in Mazor Robotics Ltd. (NASDAQ:MZOR) by 4.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,654 shares of the medical instruments supplier’s stock after selling 3,921 shares during the period. Essex Investment Management Co. LLC owned about 0.31% of Mazor Robotics worth $3,933,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its holdings in Mazor Robotics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after purchasing an additional 641 shares during the period. Royal Bank of Canada raised its holdings in shares of Mazor Robotics by 9.2% during the second quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock worth $749,000 after acquiring an additional 1,819 shares during the period. UBS Group AG raised its holdings in shares of Mazor Robotics by 2.4% during the first quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock worth $2,976,000 after acquiring an additional 2,379 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Mazor Robotics during the second quarter worth $135,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Mazor Robotics by 398.5% during the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 5,579 shares during the period. Institutional investors own 25.69% of the company’s stock.

MZOR has been the topic of a number of research analyst reports. Ladenburg Thalmann Financial Services set a $54.00 price objective on shares of Mazor Robotics and gave the stock a “buy” rating in a report on Wednesday, August 30th. Zacks Investment Research upgraded shares of Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, August 15th. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics in a report on Thursday, July 6th. Finally, Barclays PLC restated a “hold” rating and set a $34.00 price objective on shares of Mazor Robotics in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $39.83.

Mazor Robotics (NASDAQ:MZOR) last released its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The company had revenue of $15.46 million for the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the previous year, the company earned ($0.09) EPS. Mazor Robotics’s quarterly revenue was up 86.7% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Essex Investment Management Co. LLC Has $3.93 Million Holdings in Mazor Robotics Ltd. (MZOR)” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/essex-investment-management-co-llc-has-3-93-million-holdings-in-mazor-robotics-ltd-mzor/1673633.html.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Want to see what other hedge funds are holding MZOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mazor Robotics Ltd. (NASDAQ:MZOR).

Institutional Ownership by Quarter for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.